Generic Plavix® to Arrive at All Walmart and Sam's Club Pharmacies on May 19 - Marketwatch

This year a number of popular medications will be released as generic equivalents, including: Generic Substitute For Available Escitalopram Lexapro® Available Now Ibandronate Boniva® Available Now Irbesartan Avapro® Available Now Modafinil ...

3 'Big Pharma' Stocks To Consider Now - Seekingalpha.com

Since, 2008, a handful of drugs that have lost protection have cost about $5.7 billion. This year, blockbusters Plavix and Avapro come off patent as well. Genzyme, through its brief history, had specialized in treatments for relatively rare diseases and conditions.

Shorts Are Piling Into These Stocks. Should You Be Worried? - Motley Fool

Specifically, Sanofi noted that net income could fall as much as 15% this year as both Plavix and Avapro lose patent exclusivity in the United States. These drugs accounted for approximately 58 million euros of Sanofi's first-quarter revenue ...

Side Effects of Lisinopril Weight Loss - 1UP.COM

Angiotensin II receptor blockers - [Atacand (Candesartan) Teveten (Eprosartan) Avapro (Irbesarten) Cozaar (Losarten) Benicar (Olmesarten) Micardis (Telmisartan) Diovan (Valsartan)] Function: These drugs block the action (not the production) of Angiotensin ...

Teva Pharmaceuticals' Disappointing Results - Seekingalpha.com

The company recently announced that it has started selling Irbesartan and irbesarten-hydrochlorothiazide tablets, a generic version of Sanofi-Aventis' high blood pressure drugs, Avapro and Avalide tablets. Teva also has exclusivity to market the generic ...

Sanofi net profit surges by 12.5% to Euro 2.4 billion in Q1 - pharmabiz.com

Taking into account the loss of Plavix and Avapro exclusivity in the US, the performance of growth platforms, contribution from Genzyme and cost control as well as other generic competition, 2012 business EPS is expected to be 12 per cent to 15 per cent ...

Top global pharma cos post sales growth of just 3.4%, but net profit up by 12.8% in 2011 - pharmabiz.com

Similarly, Aciphex/Pariet of J&J , NeoRecormon/Epogin of Roche and Avapro/Avalide of Bristol-Myers lost blockbuster status in 2011. Besides, Lipitor and Seretide/Advair, few important blockbuster products like MabThera/Rituxan (Roche), Diovan (Novartis ...